SION Smart Money
Sionna Therapeutics, Inc.
1W: -6.8%
1M: -24.4%
3M: -91.4%
YTD: -90.1%
1Y: -90.1%
$3.87
+0.18 (+4.88%)
After Hours: $3.89 (+0.02, +0.52%)
Weekly Expected Move ±7.3%
$3
$3
$4
$4
$4
Credit Risk of going bust: higher than 96% of companies Debt: 4.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 98%), Sionna Therapeutics, Inc. would be worth roughly what it owes.
Total debt $8.1M against a stock market value of $166.6M.
Distance to default 0.24 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.0M (short-term plus half of long-term), stock volatility 255.6%; Altman Z'' 14.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 98%), Sionna Therapeutics, Inc. would be worth roughly what it owes.
Total debt $8.1M against a stock market value of $166.6M.
Distance to default 0.24 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.0M (short-term plus half of long-term), stock volatility 255.6%; Altman Z'' 14.89. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026161
Institutions Holding
+31 vs prior
1198.6%
Ownership
+176.97%
38
New
57
Increased
48
Reduced
9
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Shah Rajeev M. | director | S-Sale | 33,800 | $7.46 | $252K | Filing |
| 2026-09-17 | Kolchinsky Peter | director | S-Sale | 3,415,011 | $6.32 | $21.6M | Filing |
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P. | director | S-Sale | 33,800 | $7.46 | $252K | Filing |
| 2026-09-17 | Kolchinsky Peter | director | S-Sale | 33,800 | $7.46 | $252K | Filing |
| 2026-09-17 | RA Capital Nexus Fund III, L.P. | director | S-Sale | 33,800 | $7.46 | $252K | Filing |
| 2026-09-17 | RA Capital Nexus Fund, L.P. | director | S-Sale | 33,800 | $7.46 | $252K | Filing |
| 2026-09-17 | RA Capital Healthcare Fund LP | director | S-Sale | 33,800 | $7.46 | $252K | Filing |
| 2026-09-17 | Shah Rajeev M. | director | S-Sale | 3,415,011 | $6.32 | $21.6M | Filing |
| 2026-09-17 | Ridloff Elena | officer: cfo and cbo | A-Grant/Award | 47,268 | $— | $0 | Filing |
| 2026-09-17 | McKee Charlotte | officer: cmo and head of r&d | A-Grant/Award | 50,000 | $— | $0 | Filing |
| 2026-09-17 | Fitzpatrick Jennifer | officer: clo and head of program mgmt. | A-Grant/Award | 28,133 | $— | $0 | Filing |
| 2026-09-17 | Fitzpatrick Jennifer | officer: clo and head of program mgmt. | A-Grant/Award | 28,132 | $— | $0 | Filing |
| 2026-09-17 | Cloonan Michael | officer: president & ceo | A-Grant/Award | 109,025 | $— | $0 | Filing |
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P. | director | S-Sale | 3,415,011 | $6.32 | $21.6M | Filing |
| 2026-09-17 | RA Capital Healthcare Fund LP | director | S-Sale | 3,415,011 | $6.32 | $21.6M | Filing |
| 2026-09-17 | RA Capital Nexus Fund, L.P. | director | S-Sale | 3,415,011 | $6.32 | $21.6M | Filing |
| 2026-09-17 | RA Capital Nexus Fund III, L.P. | director | S-Sale | 3,415,011 | $6.32 | $21.6M | Filing |
| 2026-09-17 | Ridloff Elena | officer: cfo and cbo | A-Grant/Award | 47,269 | $— | $0 | Filing |
| 2026-07-07 | Thompson Peter A. | director | S-Sale | 85,918 | $44.86 | $3.9M | Filing |
| 2026-07-07 | OrbiMed Capital GP VIII LLC | director | S-Sale | 85,918 | $44.86 | $3.9M | Filing |
| 2026-07-07 | ORBIMED ADVISORS LLC | director | S-Sale | 85,918 | $44.86 | $3.9M | Filing |
| 2026-07-06 | Fitzpatrick Jennifer | officer: chief legal officer | S-Sale | 10,250 | $43.60 | $447K | Filing |
| 2026-06-30 | Thompson Peter A. | director | S-Sale | 115,844 | $45.50 | $5.3M | Filing |
| 2026-06-30 | OrbiMed Capital GP VIII LLC | director | S-Sale | 115,844 | $45.50 | $5.3M | Filing |
| 2026-06-30 | ORBIMED ADVISORS LLC | director | S-Sale | 115,844 | $45.50 | $5.3M | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9,905,045 | $436M | — | 2026-06-30 | Filing |
| TPG GP A, LLC | 6,494,962 | $286M | — | 2026-06-30 | Filing |
| VIKING GLOBAL INVESTORS LP | 3,195,181 | $141M | — | 2026-06-30 | Filing |
| Atlas Venture Life Science Advisors, LLC | 2,995,602 | $132M | — | 2026-06-30 | Filing |
| ORBIMED ADVISORS LLC | 2,555,877 | $112M | -974,825 | 2026-06-30 | Filing |
| ENAVATE SCIENCES GP, LLC | 2,478,030 | $109M | — | 2026-06-30 | Filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,600,000 | $70M | +1,450,000 | 2026-06-30 | Filing |
| BlackRock, Inc. | 1,474,769 | $65M | +178,902 | 2026-06-30 | Filing |
| JPMORGAN CHASE & CO | 1,490,508 | $64M | +25,494 | 2026-06-30 | Filing |
| JENNISON ASSOCIATES LLC | 1,172,133 | $52M | -279,087 | 2026-06-30 | Filing |
| CITADEL ADVISORS LLC | 1,147,636 | $50M | -19,295 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,132,001 | $50M | +102,504 | 2026-06-30 | Filing |
| STATE STREET CORP | 1,021,534 | $45M | +265,307 | 2026-06-30 | Filing |
| PERCEPTIVE ADVISORS LLC | 905,000 | $40M | +246,561 | 2026-06-30 | Filing |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 680,916 | $30M | -289,674 | 2026-06-30 | Filing |
| Siren, L.L.C. | 610,515 | $27M | +310,515 | 2026-06-30 | Filing |
| EVENTIDE ASSET MANAGEMENT, LLC | 474,981 | $21M | -170,549 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 457,145 | $20M | +67,273 | 2026-06-30 | Filing |
| Casdin Capital, LLC | 400,000 | $18M | +400,000 | 2026-06-30 | Filing |
| BAKER BROS. ADVISORS LP | 400,000 | $18M | — | 2026-06-30 | Filing |